To help migraine patients — and sell more medicines — major drugmakers turn to telehealth
Aug. 27, 2024
Health Tech Correspondent
In 2021, Katey Frederking had reached the end of her rope. The 29-year-old was struggling with frequent migraines, which started after a concussion from a fall on an icy patch near her home in Chicago. The medications she had been prescribed weren’t working, her doctor wasn’t listening, and she was facing several months of wait time before she could see a new neurologist.
So she took to Google and quickly signed up with Cove, a telehealth company focused on migraine care. Cove helped her get a prescription for a triptan, a class of migraine drugs available since the ’90s. When that wasn’t enough, Cove recommended one of a new class of migraine drugs that target a nerve cell protein called calcitonin gene-related peptide, or CGRP.
advertisement
“I knew exactly what I wanted and needed, and it provided me with exactly it,” Frederking told STAT about her experience with Cove. The anti-CGRP drug, Nurtec, “absolutely changed” her life.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get StartedTotals $468 per year
Starter
$20
for 3 months, then $399/year
$20 for 3 months Get StartedThen $399/year
Annual
$399
Save 15%
$399/year Get StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started$300 Annually per user
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe Log In biotechnology, health tech, Pfizer, Pharmaceuticals, STAT+ Submit a correction requestReprints
Newsletter
Tech is transforming health care and life sciences. Our original reporting is here to keep you ahead of the curve.
